How wandering gut T cells drive disease far beyond the intestine

The gut is far more than a digestive tube. It is the body’s largest immune organ, packed with billions of T lymphocytes that patrol the mucosal lining, distinguish friend from foe among trillions of microbes, and quietly decide when to attack and when to tolerate. A comprehensive new review published in the Journal of Advanced Research argues that one of the most underappreciated aspects of this system is movement itself: where intestinal T cells travel, how they get there, and what happens when those journeys go wrong. According to the review by Yadong Sun, Yuqing Liu, Lingxiang Xie, Lemei Zhu, and Weijun Peng, dysregulated T-cell trafficking is not merely a local intestinal problem but a mechanistic thread connecting inflammatory bowel disease, colorectal cancer, multiple sclerosis, glaucoma, type 1 diabetes, liver disease, and even bone loss.

The review’s central premise is that intestinal T-cell migration is neither random nor passive. It is orchestrated by a multilayered network of molecular signals that begins with the sphingosine-1-phosphate (S1P) system. S1P is a bioactive lipid whose concentration is high in the blood and low inside lymphoid tissues, creating a gradient that mature T cells sense through the S1PR1 receptor to exit the thymus and peripheral lymphoid organs. A surface molecule called CD69 provides a counterweight, promoting degradation of S1PR1 and transiently trapping activated T cells where they can receive further instruction. When this egress circuit malfunctions, as in alcohol-associated liver disease where circulating S1P levels rise abnormally, gut-derived T cells can flood into the periphery and amplify systemic immunopathology.

Once T cells leave lymphoid tissue, chemokine-receptor axes supply the directional map. Distinct T-cell subsets carry distinct receptor repertoires: Th1 cells express CXCR3 and CCR5 and respond to inflammatory chemokines such as CXCL9, CXCL10, and CXCL11; Th17 cells typically express CCR6 and, after gut imprinting, acquire CCR9 and the integrin α4β7; regulatory T cells use CCR9, CCR6, and α4β7 to reach the mucosa and maintain tolerance. Direction alone is not enough, however. Tissue entry requires integrins, molecular clamps that switch from a low-affinity resting state to a firm-binding conformation upon chemokine activation. The ligand MAdCAM-1, enriched in gut vasculature, partners with α4β7 to grant intestinal homing, while ICAM-1 and VCAM-1 mediate adhesion and transendothelial migration elsewhere. In inflammatory bowel disease, endothelial expression of all three ligands rises, and effector T cells accumulate in the mucosa in destructive numbers.

Beneath these classical signals lies a deeper layer of regulation. The cytoskeleton converts chemical cues into physical movement: actin polymerization drives leading-edge protrusion, and coordinated microtubule remodeling maintains cellular polarity. In intestinal γδ T cells, loss of the motor protein Myo1f reduces surface expression of CCR9 and α4β7 and disrupts receptor polarization, crippling adhesion and homing. Metabolism shapes migratory capacity indirectly but powerfully. Activated Th1 and Th17 cells ramp up glycolysis to fuel rapid proliferation and tissue infiltration, while regulatory T cells favor fatty acid oxidation, though even Tregs need glycolysis to migrate actively. Hypoxia stabilizes HIF-1α, which biases differentiation toward inflammatory Th17 cells at the expense of Tregs, expanding the pool of migratory effector cells. Epigenetic mechanisms then lock these programs in place, stabilizing chromatin accessibility at migration genes such as S1pr1, Klf2, Ccr7, and Cd69; pathogenic Th17-like cells in IBD carry a distinctly open, pro-inflammatory chromatin state.

Perhaps the most striking insight of the review concerns the gut microbiota, which acts as an upstream programmer of the entire migratory apparatus. Short-chain fatty acids such as butyrate promote colonic regulatory T-cell stability by enhancing histone acetylation at the Foxp3 locus, while retinoic acid produced by gut dendritic cells induces CCR9 and α4β7 expression, with the transcription factor BATF activating the Ccr9 and Itga4 gene loci. Under pathological conditions, the same microbial signals can turn malevolent: segmented filamentous bacteria induce epithelial serum amyloid A proteins that drive inflammatory Th17 differentiation, and in glaucoma models, commensal-primed β7-positive CD4 T cells acquire gut-imprinted features and contribute to retinal ganglion cell damage. The gut, in other words, licenses T cells for journeys to organs it will never see.

These journeys define what the authors call the gut-organ axes. The lung occupies a special position because it receives the entire cardiac output, acting as a vascular filter and secondary imprinting site where pulmonary dendritic cells can confer CCR4-dependent lung-homing capacity on passing T cells. In the immune-privileged central nervous system and retina, barrier remodeling can transform once-protected tissues into selective gates: in experimental autoimmune encephalomyelitis, Th17 cells first undergo α4β7-MAdCAM-1-dependent gut homing before entering the CNS, and blocking that gut step attenuates brain inflammation. Experimental colitis can upregulate MAdCAM-1 in retinal microvessels, recruiting gut-homing CD4 T cells that injure retinal neurons. Along the metabolic axis, pancreatic β cells in type 1 diabetes express CXCL10 that recruits CXCR3-positive T cells to the islets, while in non-alcoholic steatohepatitis, α4β7-mediated recruitment of CD4 T cells to liver and gut drives fibrosis, though β7 deficiency paradoxically worsens disease in other models, a vivid illustration of context dependence.

Even bone is not exempt. Estrogen deficiency expands intestinal Th17 and TNF-producing CD4 T cells, enhances their S1PR1-dependent egress, and delivers them to the bone marrow through CXCR3, where they induce CCL20 and recruit more Th17 cells, fueling osteoclast activation and bone loss. Conversely, the bone-anabolic effect of intermittent parathyroid hormone depends on microbiota-derived butyrate, which enhances Treg responses and promotes bone formation through CD8 T-cell-derived Wnt10b. The same axis that destroys bone in one hormonal context builds it in another, underscoring the review’s argument that pathological migration is a mismatch between migratory direction, cell subset, and tissue context rather than simply too much trafficking.

The therapeutic implications are already substantial. S1PR modulators such as fingolimod, ozanimod, siponimod, and etrasimod functionally antagonize S1PR1, sequestering lymphocytes in lymphoid tissues, and have transformed treatment of relapsing multiple sclerosis and ulcerative colitis, though first-generation agents’ cardiovascular side effects pushed development toward greater receptor selectivity. Integrin antagonists represent the most clinically mature class: natalizumab blocks α4 broadly but carries a risk of progressive multifocal leukoencephalopathy by impairing CNS immune surveillance, prompting the development of the gut-selective anti-α4β7 antibody vedolizumab, proven for both ulcerative colitis and Crohn’s disease. Yet even vedolizumab’s efficacy varies across populations, and a phase III trial in Chinese patients with Crohn’s disease missed its primary endpoint, likely reflecting differences in prior biologic exposure, microbiota composition, and compensatory trafficking pathways. Chemokine blockade has proven harder: the CCR5 antagonist maraviroc shows promise in graft-versus-host disease prophylaxis, but elevated CXCL9 and CXCL10 in non-responders reveal how readily the CXCR3 axis compensates, and the anti-CCR4 antibody mogamulizumab can deplete protective central memory CD8 T cells alongside its intended targets.

The review also highlights indirect and adjunctive strategies. Commonly used drugs reshape the migratory microenvironment: proton pump inhibitors can disrupt tight junctions and alter microbiota, NSAIDs activate TLR4-NF-κB signaling that creates chemotactic conditions for effector T cells, and statins may interfere with RhoA-dependent cytoskeletal remodeling. Microbiota-based interventions, including probiotics, propionate supplementation in multiple sclerosis, and fecal microbiota transplantation, show real but heterogeneous promise, with FMT success depending heavily on donor-recipient ecological matching and carrying risks of transmitting drug-resistant organisms. Even lifestyle factors matter: chronic stress elevates glucocorticoids that suppress CCR9-mediated chemotaxis and α4β7-dependent adhesion, acute exercise mobilizes cytotoxic lymphocytes into circulation, and lymphocyte trafficking follows circadian rhythms, suggesting that the timing of migration-targeted therapy could one day be optimized.

The authors conclude that the future lies not in broadly suppressing T-cell movement but in selectively restraining pathological migration while preserving barrier defense, immune surveillance, and antitumor immunity. Precision tools are emerging to support this shift: fluorescently labeled vedolizumab can visualize α4β7-positive target cells in inflamed mucosa, single-cell multi-omics and spatial transcriptomics can resolve which T-cell subsets truly drive disease, and candidate biomarkers such as soluble MAdCAM-1, circulating α4β7-positive T cells, and genetic variants in S1PR1, ITGA4, ITGB7, and CCR6 may guide patient stratification. Combination regimens such as the EXPLORER triple therapy of vedolizumab, adalimumab, and methotrexate in early Crohn’s disease offer cautious encouragement, though mechanistic complementarity does not always translate into clinical benefit, as disappointing trials of mogamulizumab plus nivolumab demonstrate. What emerges from this synthesis is a reframing of immune-mediated disease itself: not as a failure confined to a single tissue, but as a disorder of connectivity, in which the gut continuously imprints migrating T cells and distant organs decide, through their own chemotactic and adhesive gates, whether those cells heal or harm.

Subject of Research: Mechanisms of intestinal T-cell migration and its role in gut-organ axis diseases and migration-targeted therapies

Article Title: Intestinal T-cell migration: unraveling mechanisms and therapeutic implications

Article References: Sun, Y., Liu, Y., Xie, L., Zhu, L., & Peng, W. (2026). Intestinal T-cell migration: unraveling mechanisms and therapeutic implications. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.10.019

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.10.019

Keywords: T-cell migration, intestinal immunity, S1P-S1PR signaling, chemokines, integrins, gut-organ axis, inflammatory bowel disease, colorectal cancer, microbiota, vedolizumab, immune regulation, precision medicine